<DrugInformationSummary id="CDR0000709777"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about brentuximab vedotin
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/brentuximabvedotin">Brentuximab Vedotin</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000530758">brentuximab vedotin</TerminologyLink><GlossaryLink ref="CDR0000710543">brentuximab vedotin</GlossaryLink><USBrandNames><USBrandName>Adcetris</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>bren-TUK-sih-mab veh-DOH-tin</TermPronunciation><MediaLink ref="CDR0000733253" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000733254" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Brentuximab Vedotin</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3904f8dd-1aef-3490-e48f-bd55f32ed67f&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Brentuximab vedotin
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045552" dictionary="Cancer.gov" audience="Patient">Anaplastic large cell lymphoma</GlossaryTermRef></Strong>. Brentuximab vedotin is used in:<ItemizedList Style="bullet" id="_6"><ListItem>Adults whose cancer is <GlossaryTermRef href="CDR0000045921" dictionary="Cancer.gov" audience="Patient">systemic</GlossaryTermRef> and has not gotten better after treatment with <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef>.</ListItem><ListItem>Adults whose cancer has not been treated.  Brentuximab vedotin is given with <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin hydrochloride</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef>.</ListItem></ItemizedList> </ListItem>
   <ListItem><Strong>Classic <GlossaryTermRef href="CDR0000270800" dictionary="Cancer.gov" audience="Patient">Hodgkin lymphoma</GlossaryTermRef>. </Strong>Brentuximab vedotin is used:<ItemizedList Style="bullet" id="_5"><ListItem>After an <GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous stem cell transplant</GlossaryTermRef> (ASCT) in adults who have a high risk that the cancer will come back or get worse.</ListItem><ListItem>In adults whose cancer has not gotten better after an ASCT. Brentuximab vedotin is also used in adults whose cancer has not gotten better after at least two treatments with combination chemotherapy and who cannot receive an ASCT.</ListItem><ListItem>With doxorubicin hydrochloride, <GlossaryTermRef href="CDR0000637631" dictionary="Cancer.gov" audience="Patient">vinblastine sulfate</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045260" dictionary="Cancer.gov" audience="Patient">dacarbazine</GlossaryTermRef>  in adults with <GlossaryTermRef href="CDR0000045897" dictionary="Cancer.gov" audience="Patient">stage III</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045898" dictionary="Cancer.gov" audience="Patient">stage IV Hodgkin lymphoma</GlossaryTermRef> whose cancer has not been treated.</ListItem><ListItem>With doxorubicin hydrochloride, <GlossaryTermRef href="CDR0000615324" dictionary="Cancer.gov" audience="Patient">vincristine sulfate</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045189" dictionary="Cancer.gov" audience="Patient">etoposide</GlossaryTermRef>, prednisone, and <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef> in children aged 2 years and older whose cancer has not been treated and who have a high risk that the cancer will come back or get worse.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046112" dictionary="Cancer.gov" audience="Patient">Cutaneous</GlossaryTermRef> anaplastic large cell lymphoma</Strong> that is <GlossaryTermRef href="CDR0000748354" dictionary="Cancer.gov" audience="Patient">primary</GlossaryTermRef>.  Brentuximab vedotin is used in adults who have received other <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapy</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">Diffuse large B-cell lymphoma</GlossaryTermRef></Strong> or  <Strong><GlossaryTermRef href="CDR0000045710" dictionary="Cancer.gov" audience="Patient">high-grade</GlossaryTermRef> <GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell lymphoma</GlossaryTermRef>.</Strong> Brentuximab vedotin is used with <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef> in adults whose cancer has come back or didnâ€™t respond to at least two types of systemic therapy and cannot be treated with an ASCT or <GlossaryTermRef href="CDR0000771302" dictionary="Cancer.gov" audience="Patient">CAR T-cell therapy</GlossaryTermRef>.</ListItem>
   <ListItem><Strong><GlossaryTermRef href="CDR0000045794" dictionary="Cancer.gov" audience="Patient">Mycosis fungoides</GlossaryTermRef></Strong>  (a type of <GlossaryTermRef href="CDR0000046771" dictionary="Cancer.gov" audience="Patient">cutaneous T-cell lymphoma</GlossaryTermRef>). Brentuximab vedotin is used in adults whose cancer has the <GlossaryTermRef href="CDR0000796822" dictionary="Cancer.gov" audience="Patient">CD30 protein</GlossaryTermRef> and who have received other systemic therapy.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000405873" dictionary="Cancer.gov" audience="Patient">Peripheral T-cell lymphoma</GlossaryTermRef></Strong> that has the CD30 protein.  Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone in adults.</ListItem></ItemizedList>
  <Para id="_4">Brentuximab vedotin
         is also being studied in the treatment of other conditions and types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Brentuximab Vedotin</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/530758">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.39">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a611052.html">Brentuximab Vedotin</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.40"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.41">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-brentuximab-children-hodgkin-lymphoma">Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C66944">Find Clinical Trials for Brentuximab Vedotin</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2011-09-12</DateFirstPublished><DateLastModified>2025-03-07</DateLastModified></DrugInformationSummary>
